Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

XVIVO beats Q2 revenue expectations thanks to strong thorax business

XVIVO recorded net revenue of SEK 239m in the second quarter, above the analyst estimate of SEK 235.68m. Revenue rose 34% year-on-year (organic +36%), driven by the thorax segment (+53% in local currency) and the abdominal segment (+26%), while service revenue declined 25%. The company reported a net profit of SEK 16.30m (earnings per share SEK 0.52) and an operating profit of SEK 25m, and sees growth potential from increasing adoption of its technologies. » More on de.investing.com
Xvivo Perfusion boosts share despite declining thoracic business in Q3 2025

Xvivo Perfusion reports net sales of SEK 586m for Q3 2025 and organic growth of 6% (excluding heart study). The abdomen segment posts a record organic growth of 47%, while the thoracic segment shows a revenue decline of 12%. Operating cash flow was SEK 21m, liquidity stands at SEK 280m; the share rose 1.28% after the earnings call. Management is focused on CE approval of the heart technology, expanding US services and an FDA submission for the heart technology by Q2 2026. » More on de.investing.com
XVivo reports revenue decline in Q2 2025 and launches restructuring

XVivo reported net revenue of SEK 178 million for the second quarter of 2025 and negative organic growth of 11%. Gross margin remained stable at 74%, and adjusted EBITDA was 13%. The company has initiated a cost-reduction and restructuring program but maintains its strategic focus on heart and liver technologies as well as planned product launches and studies. Negative currency effects and a customer inventory reduction weighed on results; the share price fell 1.88% after the announcement. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Xvivo Perfusion has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Xvivo Perfusion had revenue of €22.28m and net profit of €3.94m

(EUR)	September 2026	YoY
Revenue	22.28m	30.19%
Gross profit	13.75m	20.73%
Net profit	3.94m	902.30%
EBITDA	4.38m	34.81%

Fundamentals

Metric	Value
Market capitalization	€574.64m
Number of shares	31.5m
52-week high/low	€28.40 - €14.44
Dividends	No
Beta	1.47
P/E ratio	49.44
PEG ratio	0.15
P/B ratio	2.81
P/S ratio	6.64

Company profile

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Name	Xvivo Perfusion
CEO	Christoffer Rosenblad
Headquarters	Mölndal, vg Sweden
Website	xvivoperfusion.com
Sector	Health Care
Industry	Health Care Technology
IPO	08/12/2016
Employees	207